CareLit · DOI-Nachweis · Pneumologie
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
DOI 10.1055/s-0036-1572233
Bibliografische Angaben
Nachweis in CareLit
Autor:innenN Dickgreber, JCH Yang, MJ Ahn, B Halmos, V Hirsh, M Hochmair, B Levy, F de Marinis, T Mok, K O'Byrne, I Okamoto, M Schuler, M Sebastian, R Shah, EH Tan, N Yamamoto, A Märten, D Massey, S Wind, D Carbone
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Afatinib 40 mg/day (oral) is approved for the treatment of pts with advanced EGFRm+ NSCLC. Dose adjustment is recommended according to pre-defined tolerability criteria. We performed post-hoc analyses on the influence of afatinib dose reduction on adverse events (AEs), pharmacokinetics (PK) and progression-free survival (PFS) in the Phase III LUX-Lung 3 (LL3) trial. Methods: All pts treated with afatinib…
Zitieren
Zitierempfehlung
N Dickgreber, JCH Yang, MJ Ahn, B Halmos, V Hirsh, M Hochmair, B Levy, F de Marinis, T Mok, K O'Byrne, I Okamoto, M Schuler, M Sebastian, R Shah, EH Tan, N Yamamoto, A Märten, D Massey, S Wind, D Carbone (2016) Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). Pneumologie (02). https://doi.org/10.1055/s-0036-1572233
Mit CareLit weiterarbeiten